IGF2BP3 and hepatocellular carcinoma: In hepatocellular carcinoma (HCC), the m6A‐modified circRAPGEF1 destabilizes ASS1 mRNA via competitive binding to IGF2BP3, driving aspartate metabolic reprogramming in liver cancer stem cells (LCSCs).